Hematologic Neoplasms (Hematological Malignancy)

Subscribe to Selected New Research on Hematologic Neoplasms

4139 relevant articles (263 outcomes, 505 trials/studies) found for this Disease

Description: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.

Also Known As:

Hematological Malignancy; Hematologic Malignancy; Hematological Malignancies; Hematological Neoplasms; Hematopoietic Malignancies; Malignancies, Hematologic; Malignancy, Hematologic; Neoplasms, Hematologic; Neoplasms, Hematopoietic; Hematologic Neoplasm; Hematological Neoplasm; Hematopoietic Malignancy; Hematopoietic Neoplasm; Malignancies, Hematological; Malignancies, Hematopoietic; Malignancy, Hematological; Malignancy, Hematopoietic; Neoplasm, Hematologic; Neoplasm, Hematological; Neoplasm, Hematopoietic; Neoplasms, Hematological; Hematologic Malignancies; Hematopoietic Neoplasms

Relationship Network

Disease Context: Research Results

Neoplasms: 387730

Neoplasms by Site: 1

Hematologic Neoplasms: 4139

Bone Marrow Neoplasms: 2

Hemic and Lymphatic Diseases

Hematologic Diseases: 1421

Hematologic Neoplasms: 4139

Bone Marrow Neoplasms: 2

Related Diseases

1.	Neoplasms (Cancer)
2.	Infection
3.	Leukemia
4.	Multiple Myeloma
5.	Hematologic Neoplasms (Hematological Malignancy)

Experts

1.	Giles, Francis J: 11 articles (07/2008 - 05/2002)
2.	Raad, Issam I: 10 articles (03/2008 - 07/2003)
3.	Kontoyiannis, Dimitrios P: 9 articles (08/2008 - 07/2003)
4.	Cortes, Jorge: 9 articles (07/2008 - 03/2003)
5.	Storb, Rainer: 7 articles (02/2008 - 08/2003)
6.	Anderson, Kenneth C: 7 articles (10/2007 - 06/2003)
7.	Kantarjian, Hagop M: 7 articles (08/2007 - 07/2002)
8.	Kantarjian, Hagop: 7 articles (03/2007 - 09/2002)
9.	Giles, Francis: 6 articles (07/2008 - 09/2002)
10.	Albitar, Maher: 6 articles (05/2008 - 09/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Hematologic Neoplasms:

1.	Cyclophosphamide (Cytoxan)FDA Link 03/01/1981 - "Continuous infusion of cyclophosphamide is a clinically effective method of ALL treatment and may have a role in the initial combination regimens for this hematologic malignancy." 01/01/2006 - "Pharmacogenetics of cyclophosphamide in patients with hematological malignancies." 09/01/2003 - "Forty-one patients with hematologic malignancies were conditioned with cyclophosphamide and total body irradiation" 01/01/2002 - "Two hundred adults with hematologic malignancies were treated in consecutive cohorts defined by increasing doses of TBI (1400, 1480, and 1560 cGy) in combination with cyclophosphamide" 01/01/2001 - "Our laboratory has recently established a cyclophosphamide (CTX) plus thymic irradiation (TI)-based nonmyeloablative conditioning protocol for the treatment of hematologic malignancies" Order ALL the reference details at left...
2.	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 11/01/1999 - "This study retrospectively analyzed the effect of G-CSF dose on peripheral blood CD34+ cell collection from 91 patients with hematologic malignancies" 04/01/2006 - "To date, an increase in hematological malignancies after short-term G-CSF use has not been detected in adult donors and no cases have been reported in children" 07/01/2004 - "For mobilization, 27 men and 20 women of median age 37 years affected with hematologic malignancies received G-CSF" 07/01/2003 - "Furthermore, the neutrophil counts to start a granulocyte-colony stimulating factor appeared to be high in ATL as compared with other hematological malignancies" 07/01/1999 - "The "G-CSF" test is a reliable test that can be used successfully for the assessment of mobilizable HPC in patients with hematologic malignancies" Order ALL the reference details at left...
3.	Etoposide (VP 16)FDA LinkGeneric 01/01/2001 - "Oral etoposide in patients with hematological malignancies: a clinical and pharmacokinetic study." 08/01/1984 - "Phase II study of etoposide (NK 171) in advanced hematological malignancies]" 10/01/2004 - "We evaluated the efficacy and safety of a VP-16 (at less than the usual dose)/CY/TBI regimen for adults with hematological malignancies who are required to receive allo-BMT" 12/01/1997 - "During the past 15 years, we have gained considerable experience with the combination of fractionated total-body irradiation (FTBI) and etoposide followed by allogeneic BMT for hematologic malignancies" 02/01/1997 - "We estimated the utility of daily oral administration of etoposide (ETOP) in 25 cases of refractory hematological malignancies who had been admitted to our hospital between February, 1988 and October, 1995" Order ALL the reference details at left...
4.	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 08/01/2003 - "Experimental Design: Because retroviral vectors are ineffective at transducing nondividing primary cells from human hematopoietic malignancies, we first evaluated nonviral techniques (electroporation and ballistic transfer) using minimalistic immunogenically defined gene expression vectors to generate B7.1 or granulocyte macrophage colony-stimulating factor (GM-CSF)-expressing BM185 cells" 06/01/1993 - "To assess whether recombinant human GM-CSF (rhGM-CSF) has a more broadly based activity in the immune system, we studied its in vivo effects on endogenously-generated killer function in patients undergoing ABMT for hematologic malignancies" 06/01/1993 - "Recombinant human GM-CSF enhances T cell-mediated cytotoxic function after ABMT for hematological malignancies." 05/01/1993 - "Granulocyte-macrophage colony stimulating factor (GM-CSF) in the treatment of hematological malignancies." 05/01/1994 - "Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) clearly hastens myeloid recovery in patients with relapsed hematologic malignancies undergoing autologous bone marrow transplantation (ABMT)" Order ALL the reference details at left...
5.	AntigensIBA 08/01/2002 - "Intracellular antigens are of major importance for immunophenotyping of hematological malignancies, and flow cytometric detection of intracellular antigens was improved by the development of new permeabilization/fixation solutions" 01/01/2008 - "Detection of humoral immune responses against WT1 antigen in patients affected by different hematological malignancies." 01/01/2008 - "The concept of antigen density appears to improve the efficiency of immune techniques in the monitoring of hematopoietic malignancies" 01/01/2008 - "Adoptive transfer of antigen (Ag)-specific T-cell lines may eradicate the relapsed hematological malignancy, and may separate the anti-leukemic effect from GvHD" 09/01/2006 - "Patients with advanced hematologic malignancies without a human leukocyte antigen-matched sibling or unrelated donor were eligible" Order ALL the reference details at left...
6.	Monoclonal AntibodiesIBA 05/01/2000 - "Several monoclonal antibodies, including Lym-1, have proven effective for treatment of hematologic malignancies" 12/01/2008 - "In recent years, there has been a tremendous increase in the number of clinical studies with monoclonal antibodies and small molecules in the treatment of hematological malignancies" 07/01/2003 - "Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan." 01/01/1983 - "In this study we have 1) recorded the prevalence of hematopoietic neoplasms (HN) in Mya arenaria within a 50 mile radius of Woods Hole, Massachusetts and 2) utilized cells from one HN bearing clam to generate a series of monoclonal antibodies" 08/01/2008 - "Treatment of hematological malignancies with monoclonal antibodies]" Order ALL the reference details at left...
7.	fludarabineIBA 09/01/2006 - "Role of fludarabine in hematological malignancies." 06/03/2005 - "These results also strongly suggest that combining fludarabine with an inhibitor of the PI3K/Akt/mTOR pathway may represent a novel therapeutic strategy for hematological malignancies." 01/01/2004 - "The introduction of nonmyeloablative fludarabine-based conditioning regimens has facilitated alloSCT, while limiting regimen-related morbidity and mortality in patients with susceptible hematological malignancies" 09/01/2000 - "BACKGROUND: Fludarabine has become a drug of prominent use in hematopoietic malignancies exhibiting indolent growth profiles" 04/01/1999 - "Fludarabine is a nucleoside analog used in the treatment of hematologic malignancies that can induce severe and prolonged immunosuppression" Order ALL the reference details at left...
8.	Cytarabine (Cytosar-U)FDA LinkGeneric 06/01/2006 - "In this study, we measured the concentration of cytarabine in saliva of nine patients with hematological malignancies who received high-dose cytarabine" 12/01/1990 - "Phase II study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate), a derivative of cytosine arabinoside, on hematological malignancies was conducted by multi-institutional cooperative group" 06/01/2006 - "High-dose cytosine arabinoside (cytarabine) is widely used, either alone or in combination with other chemotherapeutic agents, for the treatment of refractory hematological malignancies" 09/01/2003 - "Cytosine arabinoside (ara-C) is a nucleoside analog used in the treatment of hematologic malignancies" 06/01/2000 - "dFdC used jointly with Ara-C may have an important clinical implication in the treatment of CML and other hematologic malignancies in future." Order ALL the reference details at left...
9.	Methotrexate (Mexate)FDA LinkGeneric 08/01/2005 - "Methotrexate (MTX) is an effective antitumor agent that has been demonstrated to be particularly useful in the treatment of hematopoietic neoplasms but causes substantial hematologic and gastrointestinal toxicity" 07/15/1995 - "PURPOSE: The main purpose of this study was to determine influential factors related to minor leukoencephalopathy (LEP) caused by moderate-dose methotrexate (MTX) and prophylactic cranial radiotherapy (CRT) in childhood hematopoietic malignancies" 08/01/2005 - "BACKGROUND AND PURPOSE: Methotrexate is a major cause of treatment-related acute neurotoxicity in children with hematologic malignancies" 01/01/2005 - "Methotrexate (MTX) remains a mainstay in the treatment of children with hematological malignancies" 09/01/1995 - "There does not appear to be a relationship between the peak or cumulative dose or the duration of methotrexate therapy and the subsequent development of hematologic malignancy" Order ALL the reference details at left...
10.	rasburicase (Elitek)FDA Link 06/01/2006 - "We collected retrospective data for 11 adults with hematologic malignancies who received a single 6-mg dose of rasburicase" 03/01/2006 - "Analysis and protocolization of rasburicase use in patients with hematologic neoplasms]" 01/01/2006 - "We conclude that rasburicase is safe and highly effective for preventing the complications of tumor lysis syndrome in patients with hematologic malignancies." 04/01/2006 - "CONCLUSION: This study confirms that rasburicase is a safe and effective agent for the treatment of hyperuricemia associated with hematologic malignancies in pediatric patients." 08/01/2003 - "Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies." Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 12/01/2007 - "Home chemotherapy can be a feasible and potentially novel treatment option for some patients with hematologic malignancy, although the clinical course of the present patient suggested that patient selection is critical for the safe operation of home chemotherapy and that it is important to educate families on how to evaluate patients' conditions and how to cope with aggravation and admission arrangements in back-up hospitals." 03/01/2008 - "Central venous catheters (CVCs) have considerably improved the management of patients with hematological malignancies, by facilitating chemotherapy, supportive therapy and blood sampling" 01/01/1994 - "Recently, the progress of chemotherapy has improved the clinical outcome of chemotherapy for hematopoietic malignancies considerably" 12/01/1975 - "The patient with hematologic malignancy is nowadays afforded longer periods of remission through appropriate chemotherapy and, while this provides comfort and encouragement to the patient, the usual outcome is death" 03/01/2008 - "BACKGROUND: The goal of this study was to conduct an accelerated vaccination program and to determine its efficacy in patients susceptible to hepatitis B virus (HBV) receiving chemotherapy because of their hematologic malignancies" Order ALL the reference details at left...
2.	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/01/2002 - "BACKGROUND: Standard allogeneic bone marrow transplantation (BMT) offers only a small chance of cure for most adult patients with advanced hematologic malignancies" 04/01/1997 - "Successful in vitro expansion of PBMC might be helpful for gene transfer into T lymphocytes, as well as for the induction of an antitumor response, particularly for prevention and treatment of relapse of hematologic malignancies following allogeneic or autologous bone marrow transplantation." 03/19/1996 - "The option of bone marrow transplantation (BMT) significantly improved prognosis of adult patients with hematologic malignancies aged less than 50 years" 05/01/1990 - "Allogeneic bone marrow transplantation (BMT) has been used successfully to treat patients with hematological malignancies" 09/01/1994 - "Bone marrow transplantation procedure has emerged as an effective treatment for hematological malignancies" Order ALL the reference details at left...
3.	Transplants (Transplant) 05/01/2003 - "Hematopoietic stem cell transplants (HSCTs) are considered the best treatment option for many hematological malignancies, and transplant numbers have increased five-fold during the last decade" 07/01/2005 - "Allogeneic transplant offers a curative option for selected hematological malignancies and improved disease free survival in those where cure is not possible" 03/15/2001 - "CONCLUSION: A TBI dose (fractionated) > 10 Gy may not necessarily be associated with a better outcome in patients undergoing allogeneic bone-marrow transplant for hematologic malignancies." 09/01/2003 - "It is now well established that the efficacy of allogeneic hematopoietic stem cell transplant for eradicating a variety of hematologic malignancies is related to antitumor activity mediated by donor immune cells contained in the stem cell graft" 11/01/2004 - "ELIGIBILITY: All hematological malignancies and ages; accrual to end after 20 transplants of patients with AML in remission and age less than 55 years" Order ALL the reference details at left...
4.	Transplantation (Transplant Recipients) 12/01/2007 - "In contrast to other hematologic malignancies treated with high-dose therapy, autografted myeloma patients continue to relapse several years after transplantation, and few patients are cured with this modality" 01/01/2003 - "High-dose myeloablative therapy with allogeneic hematopoietic transplantation is an effective treatment for hematologic malignancies, but this approach is associated with a high risk of complications" 01/01/1997 - "High-dose chemoradiotherapy with transplantation of CD34+ PBSCs purified by the immunomagnetic bead method was thus shown to be an active and safe therapy for refractory hematological malignancies with bone marrow or peripheral blood involvement" 11/01/1986 - "One hundred forty-two patients between the ages of 1 and 17 years who survived disease-free more than 1 year after marrow transplantation for hematologic malignancy had growth and development evaluations from one to 14 years posttransplant (median 4 years)" 08/01/2006 - "To evaluate the clinical efficacy of unrelated umbilical cord blood transplantation (UCBT) on the treatment of children with hematologic malignancies and nonmalignancies, between August 2001 and June 2004, 32 patients were transplanted by using unrelated umbilical cord blood supplied by Shandong Umbilical Cord Blood Bank" Order ALL the reference details at left...
5.	Stem Cell Transplantation 01/01/2008 - "The therapeutic efficacy of donor lymphocyte infusions has been proven for patients with relapsed hematologic malignancies after allogeneic stem cell transplantation" 03/11/2008 - "Patients with hematological malignancies can be successfully treated with HLA-matched T cell-depleted allogeneic stem cell transplantation (alloSCT) and subsequent donor lymphocyte infusions (DLIs)" 07/01/2002 - "We think that non-myeloablative stem cell transplantation is a useful treatment for patients with hematological malignancy complicated with psychiatric disorders." 08/01/2006 - "The purpose of this study was to investigate the efficacy of non-myeloablative allogeneic stem cell transplantation (allo-NST) and its related technologies in hematological malignancies" 11/01/2008 - "Stem cell transplantation across HLA barriers may trigger NK cell-mediated graft-vs-leukemia effects leading to improved survival for patients with hematological malignancies" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Hematologic Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 263 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>